Evidence map›Paper›PMID 42166219›Full record

ArticleJapanese journal of clinical oncology2026

Protocol digest of a randomized controlled trial comparing transverse colectomy with extended right hemicolectomy for Stage II/III transverse colon cancer: JCOG2304 (TACTICS).

Tetsuya Sekita, Tomonori Akagi, Ryo Sadachi, Takumi Hasegawa, Hidefumi Shiroshita, Haruhiko Fukuda, Takeshi Suto, Akio Shiomi, Manabu Shiozawa, Shunsuke Tsukamoto and 5 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Japanese journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Tetsuya SekitaJapan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo 104-0045, Japan.ORCID 0000-0002-4000-6891
Tomonori AkagiDepartment of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Oita 879-5593, Japan.ORCID 0000-0002-0722-0343
Ryo SadachiJapan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo 104-0045, Japan.
Takumi HasegawaDepartment of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Oita 879-5593, Japan.
Hidefumi ShiroshitaDepartment of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Oita 879-5593, Japan.
Haruhiko FukudaJapan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo 104-0045, Japan.
Takeshi SutoDepartment of Gastroenterological Surgery, Yamagata Prefectural Central Hospital, Yamagata, 990-2292, Japan.
Akio ShiomiDivision of Colon and Rectal Surgery, Shizuoka Cancer Center, Shizuoka, 411-8777, Japan.ORCID 0000-0001-5657-8686
Manabu ShiozawaDepartment of Colorectal Surgery, Kanagawa Cancer Center, Yokohama, 241-8515, Japan.
Shunsuke TsukamotoDepartment of Colorectal Surgery, National Cancer Center Hospital, Tokyo 104-0045, Japan.ORCID 0000-0001-5143-6312
Yusuke SanoJapan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo 104-0045, Japan.ORCID 0000-0001-7753-8712
Ryosuke KitaJapan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo 104-0045, Japan.
Yukihide KanemitsuDepartment of Colorectal Surgery, National Cancer Center Hospital, Tokyo 104-0045, Japan.ORCID 0000-0002-3366-3826
Masafumi InomataDepartment of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Oita 879-5593, Japan.ORCID 0000-0002-8475-3688
Japan Clinical Oncology Group Colorectal Cancer Study Group

Funding

AMED JP25ck0106076National Cancer Center Research and Development Fund 2023-J-03
6 · The paper itself

Abstract

Transverse colon cancer is traditionally treated with extended right hemicolectomy (EHC), which involves division of the middle colic, right colic, and ileocolic arteries, along with removal of the terminal ileum and right colon. Transverse colectomy (TC) is a limited resection removing only 10 cm of bowel on either side of the tumor, along with resection of the middle colic artery and regional lymphadenectomy. This approach may contribute to the preservation of bowel function without compromising oncologic adequacy. This multicenter, randomized, phase III trial is designed to evaluate the non-inferiority of TC compared with EHC in terms of relapse-free survival among patients with Stage II/III transverse colon cancer whose main feeding artery is the middle colic artery. In total, 510 patients will be enrolled across major Japanese centers over 5 years. The trial has been registered with the Japan Registry of Clinical Trials (jRCT1030240479).

Indexed as

ColectomyColonic NeoplasmsColon, TransverseClinical Trials, Phase III as TopicDisease-Free SurvivalHumansJapanLymph Node ExcisionMulticenter Studies as TopicNeoplasm StagingRandomized Controlled Trials as Topicextended right hemicolectomyquality of liferelapse-free survivalStage II/III transverse colon cancertransverse colectomy

Identifiers

PMID42166219
PMCPMC13556375

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.